Aims/Methods: We established age- and sex-related reference ranges for serum insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) levels in 807 healthy Turkish children (428 boys, 379 girls), and constructed a model for calculation of standard deviation scores of IGF-I and IGFBP-3 according to age, sex and pubertal stage. Results: Serum IGF-I and IGFBP-3 concentrations tended to be higher in girls compared to boys of the same ages, but the differences were statistically significant only in pubertal ages (9–14 years) for IGF-I and only in prepubertal ages for IGFBP-3 (6–8 years) (p < 0.05). Peak IGF-I concentrations were observed earlier in girls than boys (14 vs. 15 years, Tanner stage IV vs. V) starting to decline thereafter. IGFBP-3 levels peaked at age 13 and at Tanner stage IV in both sexes with a subsequent fall. Serum levels of IGF-I and IGFBP-3 increased steadily with age in the prepubertal stage followed by a rapid increase in IGF-I in the early pubertal stages. A relatively steeper increase in IGF-I but not in IGFBP-3 levels was observed at age 10–11 years in girls and at 12–13 years in boys which preceded the reported age of pubertal growth spurt. At late pubertal stages, both IGF-I and IGFBP-3 either did not change or decreased by increasing age. Interrelationships between growth factors and anthropometric measurements have been described, and the physiologic consequences of these have been discussed in detail. Conclusions: Differences in the pattern of IGF-I and IGFBP-3 in the present paper and those reported in other studies emphasize the importance of locally established reference ranges. Establishment of this reference data and a standard deviation score prediction model based on age, sex and puberty will enhance the diagnostic power and utility of IGF-I and IGFBP-3 in evaluating growth disorders in our population.

Keywords:
Insulin-like growth factor-I, Insulin-like growth factor binding protein-3, Puberty, IGF-I and IGFBP-3 levels, Healthy children, IGF-I and IGFBP-3 levels, IGF-I and IGFBP-3, reference ranges
1.
Blum WF, Albertsson-Wikland K, Rosberg S, Ranke MB: Serum levels of insulin-like growth factor I (IGF-I) and IGF binding protein-3 reflect spontaneous growth hormone secretion. J Clin Endocrinol Metab 1993;76:1610–1616.
2.
Zapf J, Walter H, Froesch ER: Radioimmunological determination of insulin-like growth factors I and II in normal subjects and in patients with growth disorders and extrapancreatic tumor hypoglycemia. J Clin Invest 1981;68:1321–1330.
3.
Furlanetto RW, Underwood LE, Van Wyk JJ, D’Ercole AJ: Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay. J Clin Invest 1977;60:648–657.
4.
Rosenfeld RG, Wilson DM, Lee PD, Hintz RL: Insulin-like growth factors I and II in evaluation of growth retardation. J Pediatr 1986;109:428–433.
5.
Juul A, Skakkebaek NE: Prediction of the outcome of growth hormone provocative testing in short children by measurement of serum levels of insulin-like growth factor I and insulin-like growth factor binding protein 3. J Pediatr 1997;130:197–204.
6.
Blum WF, Ranke MB: Use of insulin-like growth factor-binding protein 3 for the evaluation of growth disorders. Horm Res 1990;33(suppl 4):31–37.
7.
Arosio M, Garrone S, Bruzzi P, Faglia G, Minuto F, Barreca A: Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF)-I, and IGF-binding protein-1, -2, and -3. J Clin Endocrinol Metab 2001;86:1091–1098.
8.
Stoffel-Wagner B, Springer W, Bidlingmaier F, Klingmuller D: A comparison of different methods for diagnosing acromegaly. Clin Endocrinol (Oxf) 1997;46:531–537.
9.
Van der Lely AJ, de Herder WW, Janssen JA, Lamberts SW: Acromegaly: the significance of serum total and free IGF-I and IGF-binding protein-3 in diagnosis. J Endocrinol 1997;155(suppl 1):S9–S13.
10.
Jorgensen JO, Blum WF, Moller N, Ranke MB, Christiansen JS: Circadian patterns of serum insulin-like growth factor (IGF)-II and IGF binding protein 3 in growth hormone-deficient patients and age- and sex-matched normal subjects. Acta Endocrinol (Copenh) 1990;123:257–262.
11.
Lee KW, Cohen P: Individualizing growth hormone dosing in children. Horm Res 2001;56(suppl 1):29–34.
12.
Cohen P, Bright GM, Rogol AD, Kappelgaard AM, Rosenfeld RG, American Norditropin Clinical Trials Group: Effects of dose and gender on the growth and growth factor response to GH in GH-deficient children: implications for efficacy and safety. J Clin Endocrinol Metab 2002;87:90–98.
13.
Tillmann V, Patel L, Gill MS, Whatmore AJ, Price DA, Kibirige MS, Wales JK, Clayton PE: Monitoring serum insulin-like growth factor-I (IGF-I), IGF binding protein-3 (IGFBP-3), IGF-I/IGFBP-3 molar ratio and leptin during growth hormone treatment for disordered growth. Clin Endocrinol (Oxf) 2000;53:329–336.
14.
Paramo C, Andrade O MA, Fluiters E, Luna R, de la Fuente J, Garcia-Mayor RV: Comparative study of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) level and IGF-I/IGFBP-3 ratio measurements and their relationship with an index of clinical activity in the management of patients with acromegaly. Metabolism 1997;46:494–498.
15.
Juul A, Bang P, Hertel NT, Main K, Dalgaard P, Jorgensen K, Muller J, Hall K, Skakkebaek NE: Serum insulin-like growth factor-l in 1,030 healthy children, adolescents and adults; relation to age, sex, stage of puberty, testicular size and body mass index. J Clin Endocrinol Metab 1994;78:744–752.
16.
Juul A, Dalgaard P, Blum WF, Bang P, Hall K, Michaelsen KF, Muller J, Skakkebaek NE: Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol Metab 1995;80:2534–2542.
17.
Kawai N, Kanzaki S, Takano-Watou S, Tada C, Yamanaka Y, Miyata T, Oka M, Seino Y: Serum-free insulin-like growth factor I (IGF-I), total IGF-I, and IGF-binding protein-3 concentrations in normal children and children with growth hormone deficiency. J Clin Endocrinol Metab 1999;84:82–89.
18.
Brabant G, von zur Muhlen A, Wuster C, Ranke MB, Kratszsch J, Kiess W, Ketelslegers JM, Wilhelmsen L, Hulthen L, Saller B, Mattsson A, Wilde J, Schemer R, Kann P, German KIMS Board: Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: result from a multicenter study. Horm Res 2003;60:53–60.
19.
Ranke MB, Schweizer R, Elmlinger MW, Weber K, Binder G, Schwarze CP, Wollmann HA: Significance of basal IGF-I, IGFBP-3 and IGFBP-2 measurements in the diagnostics of short stature in children. Horm Res 2000;54:60–68.
20.
Elmlinger MW, Kuhnel W, Weber MM, Ranke MB: Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3). Clin Chem Lab Med 2004;42:654–664.
21.
Wong WW, Copeland KC, Hergenroeder AC, Hill RB, Stuff JE, Ellis KJ: Serum concentrations of insulin, insulin-like growth factor-I and insulin-like growth factor binding proteins are different between white and African-American girls. J Pediatr 1999;135:296–300.
22.
Platz EA, Pollak MN, Rimm EB, Majeed N, Tao Y, Willett WC, Giovannucci E: Racial variation in insulin-like growth factor-1 and binding protein-3 concentrations in middle-aged men. Cancer Epidemiol Biomarkers Prev 1999;8:1107–1110.
23.
Shibata A, Harris DT, Billings PR: Concentrations of estrogens and IGFs in umbilical cord blood plasma: a comparison among Caucasian, Hispanic, and Asian-American females. J Clin Endocrinol Metab 2002;87:810–815.
24.
Quarmby V, Quan C, Ling V, Compton P, Canova-Davis E: How much insulin-like growth factor I (IGF-I) circulates? Impact of standardization on IGF-I assay accuracy. J Clin Endocrinol Metab 1998;83:1211–1216.
25.
Lofqvist C, Andersson E, Gelander L, Rosberg S, Blum WF, Albertsson Wikland K: Reference values for IGF-I throughout childhood and adolescence: a model that accounts simultaneously for the effect of gender, age, and puberty. J Clin Endocrinol Metab 2001;86:5870–5876.
26.
Lofqvist C, Andersson E, Gelander L, Rosberg S, Hulthen L, Blum WF, Albertsson Wikland K: Reference values for insulin-like growth factor-binding protein-3 (IGFBP-3) and ratio IGF-I/IGFBP-3 throughout childhood and adolescence. J Clin Endocrinol Metab 2005;86:5870–5876.
27.
Neyzi O, Yalcindag A, Alp H: Heights and weights of Turkish children. J Trop Pediatr Environ Child Health 1973;19:5–13.
28.
Miles LE, Lipschitz DA, Bieber CP, Cook JD: Measurement of serum ferritin by a two-site immunoradiometric assay. Analyt Biochem 1974;61:209–224.
29.
Daughaday WH, Rotwein P: Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev 1989;10:68–91.
30.
Cara JF, Rosenfield RL, Furlanetto RW: A longitudinal study of the relationship of plasma somatomedin-C concentration to the pubertal growth spurt. Am J Dis Child 1987;141;562–564.
31.
Rosenfield RI, Furlanetto R, Bock D: Relationship of somatomedin-C concentrations to pubertal changes. J Pediatr 1983;103:723–728.
32.
Argente J, Barios V, Pozo J, Mumnoz MT, Hervas F, Stene M, Hernandez M: Normative data for insulin-like growth factors (IGFs), IGF-binding proteins, and growth hormone-binding protein in a healthy Spanish pediatric population: age- and sex-related changes. J Clin Endocrinol Metab 1993;77:1522–1528.
33.
Olivie MAA, Garcia-Mayor RV, Leston DG, Sousa TR, Dominguez AS, Alvarez-Novoa R, Cotizas JA: Serum insulin-like growth factor (IGF) binding protein-3 and IGF-I levels during childhood and adolescence. A cross-sectional study. Pediatr Res 1995;38:149–155.
34.
Gourmelen M, Le Bouc Y, Girard F, Binoux M: Serum levels of insulin-like growth factor (IGF) and IGF binding protein in constitutionally tall children and adolescents. J Clin Endocrinol Metab 1984;59:1197–1203.
35.
Ulijaszek SJ: Serum insulin-like growth factor-I, insulin-like growth factor binding protein-3, and the pubertal growth spurt in the female rhesus monkey. Am J Phys Anthropol 2002;118:77–85.
36.
Rikken B, van Doorn J, Ringeling A, Van den Brande JL, Massa G, Wit JM: Plasma levels of insulin-like growth factor (IGF)-I, IGF-II and IGF-binding protein-3 in the evaluation of childhood growth hormone deficiency. Horm Res 1998;50:166–176.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.